Skip to main content

Table 3 Summary of the base case analysis

From: Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine

Ā 

Intervention

Estimated

5-year costs

QALY gained

Difference (cost)

Difference (QALY)

Cost per QALY

deterministic

Mezavant

4,940 ā‚¬

3.320

-624 ā‚¬

0.011

NA

Ā 

Asacol

5,564 ā‚¬

3.309

Ā Ā Ā 

probabilistic

Mezavant

4,939 ā‚¬

3.320

-705 ā‚¬

0.022

NA

Ā 

Asacol

5,644 ā‚¬

3.330

Ā Ā Ā